The SNUR (as the amendment is called), according to the information disclosed in the list, would be adopted by the Council of Ministers in the 2nd quarter of 2025, and it seems that it could be an even more extensive and comprehensive amendment to the provisions of the Reimbursement Act than the DNUR adopted in 2023. This is because the information contained in the list of legislative and programmatic work of the Council of Ministers on the solutions to be introduced by this law counts as many as 52 points. Most of the changes indicated in it concern issues that were previously announced by the Ministry of Health, such as:
- The abolition of the requirement to submit in the application for reimbursement a declaration of future supplies in accordance with the formula that is currently regulated by the law - as the algorithm has been found to be flawed and to lead to incorrectly established declarations of supplies;
- Removal from the law of the provision on the obligation to supply scarce drugs in equal quantities to the 10 largest full-line wholesalers - this provision has proven to be unworkable in practice;
- Reinstating the obligation to reduce the net selling price by 25 percentage points only on the expiration of market exclusivity, and not on the expiration of a drug's patent, given the sometimes very complicated patent protection regimes that apply to individu...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in